Ginsenoside Rg1 attenuates oligomeric Aβ1-42-induced mitochondrial dysfunction

Current Alzheimer Research

Volumn 9, Issue 3, 2012, Pages 388-395

  Huang, Tianwen ^a   Fang, Fang ^b   Chen, Limin ^a   Zhu, Yuangui ^a   Zhang, Jing ^a   Chen, Xiaochun ^a   Yan, Shirley Shidu ^b  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

Alzheimer's disease; Ginsenoside Rg1; Mitochondria; Oligomeric beta amyloid peptide1 42

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMYLOID BETA PROTEIN[1-42]; CYTOCHROME C; CYTOCHROME C OXIDASE; GINSENOSIDE RG 1; OLIGOMER;

ANIMAL CELL; ARTICLE; ATTENUATION; BRAIN CELL; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME ACTIVITY; FETUS; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NERVE CELL LESION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CELL DEATH; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM AGENTS; FEMALE; GINSENOSIDES; MICE; MICE, INBRED C57BL; MITOCHONDRIAL DISEASES; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; PRIMARY CELL CULTURE;

EID: 84860280814     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720512800107636     Document Type: Article

References (47)

1. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 256: 184-5 (1992).
2. Haass C, Steiner H. Protofibrils, the unifying toxic molecule of neurodegenerative disorders? Nat Neurosci 4: 859-60 (2001).
3. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-6 (2002).
4. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440: 352-7 (2006).
5. Shankar GM, Li S, Mehta TH, Shepardson NE, Smith I, Brett FM, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14(8): 837-42 (2008).
6. Chen JX, Yan SD. Amyloid-beta-Induced Mitochondrial Dysfunction. J Alzheimers Dis 12: 177-84 (2007).
7. Takuma K, Yao J, Huang J, Xu H, Chen X, Luddy J, et al. ABAD enhances Abeta-induced cell stress via mitochondrial dysfunction. FASEB J 19: 597-8 (2005).
8. Caspersen C, Wang N, Yao J, Sosunov A, Chen X, Lustbader JW, et al. Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J 19: 2040-1(2005).
9. Du H, Guo L, Fang F, Chen D, Sosunov AA, McKhann GM, et al. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat Med 14: 1097-105 (2008).
10. Lustbader JW, Cirilli M, Lin C, Xu HW, Takuma K, Wang N, et al. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 304: 448-52 (2004).
11. Yao J, Du H, Yan S, Fang F, Wang C, Lue LF, et al. Inhibition of amyloid-beta (Abeta) peptide-binding alcohol dehydrogenase-Abeta interaction reduces Abeta accumulation and improves mitochondrial function in a mouse model of Alzheimer's disease. J Neurosci 31: 2313-20 (2011).
12. Manczak M, Anekonda TS, Henson E, Park BS, Quinn J, Reddy PH. Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet 15: 1437-49 (2006).
13. Dragicevic N, Mamcarz M, Zhu Y, Buzzeo R, Tan J, Arendash GW, et al. Mitochondrial amyloid-beta levels are associated with the extent of mitochondrial dysfunction in different brain regions and the degree of cognitive impairment in Alzheimer's transgenic mice. J Alzheimers Dis 20(2): S535-50 (2010).
14. Chen JX, Yan SS. Role of mitochondrial amyloid-beta in Alzheimer's disease. J Alzheimers Dis 20(2): S569-78 (2010).
15. Du H, Guo L, Zhang W, Rydzewska M, Yan S. Cyclophilin D deficiency improves mitochondrial function and learning/memory in aging Alzheimer disease mouse model. Neurobiol Aging 32(3): 398-406 (2011).
16. Yao J, Irwin RW, Zhao L, Nilsen J, Hamilton RT, Brinton RD. Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 106: 14670-5 (2009).
17. Moreira PI, Cardoso SM, Santos MS, Oliveira CR. The key role of mitochondria in Alzheimer's disease. J Alzheimers Dis 9: 101-10 (2006).
18. Moreira PI, Santos MS, Oliveira CR. Alzheimer's disease: a lesson from mitochondrial dysfunction. Antioxid Redox Signal 9: 1621-30 (2007).
19. Moreira PI, Duarte AI, Santos MS, Rego AC, Oliveira CR. An integrative view of the role of oxidative stress, mitochondria and insulin in Alzheimer's disease. J Alzheimers Dis 16: 741-61 (2009).
20. Swerdlow RH, Khan SM. The Alzheimer's disease mitochondrial cascade hypothesis: an update. Exp Neurol 218: 308-15 (2009).
21. Cheng Y, Shen LH, Zhang JT. Anti-amnestic and anti-aging effects of ginsenoside Rg1 and Rb1 and its mechanism of action. Acta Pharmacol Sin 26:143-9 (2005).
22. Chen F, Eckman EA, Eckman CB. Reductions in levels of the Alzheimer's amyloid beta peptide after oral administration of ginsenosides. FASEB J 20: 1269-71 (2006).
23. Shi YQ, Huang TW, Chen LM, Pan XD, Zhang J, Zhu YG, et al. Ginsenoside Rg1 attenuates amyloid-beta content, regulates PKA/CREB activity, and improves cognitive performance in SAMP8 mice. J Alzheimers Dis 19: 977-89 (2010).
24. Wei C, Jia J, Liang P, Guan Y. Ginsenoside Rg1 attenuates betaamyloid-induced apoptosis in mutant PS1 M146L cells. Neurosci Lett 443: 145-9 (2008).
25. Xu H, Jiang H, Wang J, Xie J. Rg1 protects iron-induced neurotoxicity through antioxidant and iron regulatory proteins in 6-OHDAtreated MES23.5 cells. J Cell Biochem 111: 1537-45 (2010).
26. Zhu D, Wu L, Li CR, Wang XW, Ma YJ, Zhong ZY, et al. Ginsenoside Rg1 protects rat cardiomyocyte from hypoxia/reoxygenation oxidative injury via antioxidant and intracellular calcium homeostasis. J Cell Biochem 108: 117-24 (2009).
27. Leung KW, Yung KK, Mak NK, Chan YS, Fan TP, Wong RN. Neuroprotective effects of ginsenoside-Rg1 in primary nigral neurons against rotenone toxicity. Neuropharmacology 52: 827-35 (2007).
28. Brewer GJ, Torricelli JR, Evege EK, Price PJ. Optimized survival of hippocampal neurons in B27-supplemented Neurobasal, a new serum-free medium combination. J Neurosci Res 35: 567-76 (1993).
29. Chen X, Stern D, Yan SD. Mitochondrial dysfunction and Alzheimer's disease. Curr Alzheimer Res 3: 515-20 (2006).
30. Atamna H, Frey WH 2nd. Mechanisms of mitochondrial dysfunction and energy deficiency in Alzheimer's disease. Mitochondrion 7: 297-310 (2007).
31. Du H, Guo L, Yan S, Sosunov AA, McKhann GM, Yan SS. Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model. Proc Natl Acad Sci USA 107: 18670-5 (2010).
32. Pickrell AM, Fukui H, Moraes CT. The role of cytochrome c oxidase deficiency in ROS and amyloid plaque formation. J Bioenerg Biomembr 41: 453-6 (2009).
33. Valla J, Schneider L, Niedzielko T, Coon KD, Caselli R, Sabbagh MN, et al. Impaired platelet mitochondrial activity in Alzheimer's disease and mild cognitive impairment. Mitochondrion 6: 323-30 (2006).
34. Chen X, Stern D, Yan SD. Cellular targets of amyloid beta peptide: potential roles in neuronal cell stress and toxicity. Third ed. Oxford Publication (2007).
35. Nicholls DG, Budd SL. Mitochondria and neuronal survival. Physiol Rev 80: 315-60 (2000).
36. DiPietrantonio AM, Hsieh T, Wu JM. Activation of caspase 3 in HL-60 cells exposed to hydrogen peroxide. Biochem Biophys Res Commun 255: 477-82 (1999).
37. Matsura T, Kai M, Fujii Y, Ito H, Yamada K. Hydrogen peroxideinduced apoptosis in HL-60 cells requires caspase-3 activation. Free Radic Res 30: 73-83 (1999).
38. Chauhan V, Chauhan A. Oxidative stress in Alzheimer's disease. Pathophysiology 13: 195-208 (2006).
39. Chen JX, Yan SS. Role of mitochondrial amyloid-beta in Alzheimer's disease. J Alzheimers Dis 20 (2): S569-78 (2010).
40. Swerdlow RH, Kish SJ. Mitochondria in Alzheimer's disease. Int Rev Neurobiol 53: 341-85 (2002).
41. Cardoso SM, Santana I, Swerdlow RH, Oliveira CR. Mitochondria dysfunction of Alzheimer's disease cybrids enhances Abeta toxicity. J Neurochem 89: 1417-26 (2004).
42. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 362: 29-44 (2010).
43. Swerdlow RH. Mitochondria in cybrids containing mtDNA from persons with mitochondriopathies. J Neurosci Res 85: 3416-28 (2007).
44. Swerdlow RH, Parks JK, Cassarino DS, Maguire DJ, Maguire RS, Bennett JP Jr, et al. Cybrids in Alzheimer's disease: a cellular model of the disease? Neurology 49: 918-25 (1997).
45. Tanaka N, Goto Y, Akanuma J, Kato M, Kinoshita T, Yamashita F, et al. Mitochondrial DNA variants in a Japanese population of patients with Alzheimer's disease. Mitochondrion 10: 32-7 (2010).
46. Dumont M, Lin MT, Beal MF. Mitochondria and antioxidant targeted therapeutic strategies for Alzheimer's disease. J Alzheimers Dis 20 Suppl 2: S633-43 (2010).
47. Chen XC, Zhou YC, Chen Y, Zhu YG, Fang F, Chen LM. Ginsenoside Rg1 reduces MPTP-induced substantia nigra neuron loss by suppressing oxidative stress. Acta Pharmacol Sin 26: 56-62 (2005).